Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $998.2 million.

  • BridgeBio Pharma's Liabilities and Shareholders Equity rose 5011.8% to $998.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 billion, marking a year-over-year increase of 3587.84%. This contributed to the annual value of $919.3 million for FY2024, which is 6825.98% up from last year.
  • Per BridgeBio Pharma's latest filing, its Liabilities and Shareholders Equity stood at $998.2 million for Q3 2025, which was up 5011.8% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Liabilities and Shareholders Equity registered a high of $1.1 billion during Q1 2021, and its lowest value of $503.7 million during Q2 2023.
  • Over the past 5 years, BridgeBio Pharma's median Liabilities and Shareholders Equity value was $813.1 million (recorded in 2022), while the average stood at $816.6 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first tumbled by 4158.64% in 2023, then skyrocketed by 6825.98% in 2024.
  • Quarter analysis of 5 years shows BridgeBio Pharma's Liabilities and Shareholders Equity stood at $1.0 billion in 2021, then plummeted by 38.48% to $623.0 million in 2022, then dropped by 12.3% to $546.4 million in 2023, then soared by 68.26% to $919.3 million in 2024, then grew by 8.58% to $998.2 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $998.2 million for Q3 2025, versus $1.1 billion for Q2 2025 and $881.6 million for Q1 2025.